DMF was associated with lower annualized relapse rates (ARR) and improvement on patient reported outcomes (PROs) in patients with relapsing multiple sclerosis (RMS) who switch to DMF following suboptimal response to glatiramer acetate (GA).
Patients with relapsing-remitting multiple sclerosis (MS) had fewer relapses after switching from glatiramer acetate to fingolimod versus remaining on the injectable disease-modifying therapy
Delayed-release dimethyl fumarate (DMF) is associated with better control of multiple sclerosis (MS)-associated declines in work productivity than the injectable platform therapies
At 12 months, patients with relapsing-remitting multiple sclerosis (MS) treated with dimethyl fumarate and fingolimod had similar rates of overall efficacy and adherence, but patients discontinued dimethyl fumigate earlier than fingolimod.
In the “real world,” patients with multiple sclerosis (MS) who experienced relapses while on oral medications did so at a rate comparable to that of clinical trials; however, adverse effects were higher than those observed in clinical trials.
The advantages of fingolimod over injectable disease-modifying therapies (iDMTs) in patient retention and treatment satisfaction support use of fingolimod in early relapsing-remitting multiple sclerosis (MS) in the real world.
Data from patients with relapsing-remitting multiple sclerosis (MS) who received the humanized monoclonal antibody daclizumab high-yield process (HYP) “extend previous observations” on the agent’s rapid pharmacodynamic effects on CD56bright natural killer (NK) cells and regulatory T-cells (Tregs) at treatment initiation, providing additional evidence for an immunomodulatory effect.
Dietary sodium intake is not associated with MS risk in a prospective cohort of women from the Nurses’ Health Study and Nurses’ Health Study II
Vitamin D can enhance the therapeutic benefits of interferon-beta (IFN-beta) in patients with various forms of MS.
No difference in serum vitamin D levels was found between patients with multiple sclerosis (MS) and positive anti-drug antibodies (ADA) vs negative ADA in samples taken 1 year after interferon-β treatment was initiated.
Please login or register first to view this content.
